
Beyond Geography: Dynamic Operating Models for Market Expansion and Portfolio Transitions
Geography is a good starting point, but building a Global-Local operating model is about much more than proximity.
Read More

Insights from Coupa and Acquis Consulting Group on T&E Spending
T&E spend is typically the 2nd largest controllable expense
The pandemic changed everything — travel spend decreased but remained flat in many cases
Budgets were reallocated to accommodate the changing working environment
Opportunities to Reimagine and Redesign T&E Spend Management
You don’t want people to feel like people are being watched. We must work towards a trusted but verified and respectful culture.
Leverage community buying power to pre-negotiate optimum pricing.
Technology can help eliminate fraud, biases, and optimize spend.
5% of business expense is fraud. It is important to have technology on your side to make sure fraud is not happening.
Four main considerations when reevaluating your T&E program:
Create processes that don’t disrupt existing workflows
Document current spends habits into formalized expense policy
Better user experience = more adoption = better control
Spend has shifted to accommodate new working styles and changing business needs
Evaluate and consolidate new areas of spend
Spend consolidation = greater visibility = deeper insights
T&E fraud has increased overall during pandemic
Build a culture of trust and verification
Consider non-punitive audits
Unpredictability in spend isn’t a problem, it can be an asset
Just because it’s post-approved spend doesn’t mean you can’t influence it or optimize it
Make your T&E spend work for you
If you want to stay ahead of the curve, you need to shift from tactical T&E management to strategic.


Subscribe to the Acquis newsletter

Geography is a good starting point, but building a Global-Local operating model is about much more than proximity.
Read More

Combinations are not new. What is new is the velocity. The number of regimens pairing established immuno-oncology (IO) agents with novel molecules and mechanisms has grown significantly year over year, and the data supporting those pairings is maturing in ways that carry real implications for patients, drugmakers, and the broader life sciences investment thesis.
Read More

Coupa Inspire 2026 marked Coupa's 20th anniversary, and the conference reflected a company positioning itself for a new phase of growth. Coupa is building its roadmap around AI-enabled workflows, automation, and orchestration across the full spend lifecycle.
Read More

Geography is a good starting point, but building a Global-Local operating model is about much more than proximity.
Read More

Combinations are not new. What is new is the velocity. The number of regimens pairing established immuno-oncology (IO) agents with novel molecules and mechanisms has grown significantly year over year, and the data supporting those pairings is maturing in ways that carry real implications for patients, drugmakers, and the broader life sciences investment thesis.
Read More

Coupa Inspire 2026 marked Coupa's 20th anniversary, and the conference reflected a company positioning itself for a new phase of growth. Coupa is building its roadmap around AI-enabled workflows, automation, and orchestration across the full spend lifecycle.
Read More